.jpg "Booz Allen (NYSE: BAH)")
There’s a lot to be optimistic about in the Services sector as 3 analysts just weighed in on Booz Allen (NYSE: BAH), Dick’s Sporting Goods (NYSE: DKS) and TapImmune Inc (NASDAQ: TPIV) with bullish sentiments.
Booz Allen (NYSE: BAH)
In a report released today, Tobey Sommer from SunTrust Robinson maintained a Buy rating on Booz Allen (NYSE: BAH), with a price target of $51. The company’s shares closed yesterday at $44.02, close to its 52-week high of $44.17.
According to TipRanks.com, Sommer is a 5-star analyst with an average return of 17.4% and a 68.9% success rate. Sommer covers the Services sector, focusing on stocks such as AMN Healthcare Services Inc, Cross Country Healthcare, and Korn/Ferry International.
Currently, the analyst consensus on Booz Allen is Moderate Buy and the average price target is $54, representing a 22.7% upside.
In a report issued on May 18, Cowen & Co. also assigned a Buy rating to the stock with a $50 price target.
See today’s analyst top recommended stocks >>
Dick’s Sporting Goods (NYSE: DKS)
Susquehanna analyst Sam Poser assigned a Buy rating to Dick’s Sporting Goods (NYSE: DKS) today. The company’s shares closed yesterday at $30.48.
According to TipRanks.com, Poser is a 5-star analyst with an average return of 8.6% and a 57.7% success rate. Poser covers the Consumer Goods sector, focusing on stocks such as Wolverine World Wide, Deckers Outdoor, and Steven Madden.
Dick’s Sporting Goods has an analyst consensus of Hold, with a price target consensus of $33.80.
TapImmune Inc (NASDAQ: TPIV)
In a report released today, Stephen Brozak from WBB Securities maintained a Buy rating on TapImmune Inc (NASDAQ: TPIV). The company’s shares closed yesterday at $4.10.
Brozak commented:
“We have previously commented in a note our continued interest in TPIV’s strategic move to merge with Marker, as the clinical assets carry data that cannot be overlooked, and the proposed management, advisory, as well as directorship of the combined company place prominence on TPIV to be a leader in the cell therapy space. We are reiterating that thesis in this report and again look with greater enthusiasm towards the closing of this transaction and the development of a new company. We therefore raising our and maintaining our price target of $5.50.”
According to TipRanks.com, Brozak is a 4-star analyst with an average return of 15.6% and a 53.1% success rate. Brozak covers the Healthcare sector, focusing on stocks such as Melinta Therapeutics Inc, Cidara Therapeutics, and Omeros Corp.
TapImmune Inc has an analyst consensus of Moderate Buy.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
